McKesson Corp. Reports Rise In Q3 Bottom Line

McKesson reported Q3 GAAP net income of $1.186 billion, or $9.59 per share, versus $879 million, or $6.95 per share a year earlier; adjusted earnings were $1.155 billion, or $9.34 per share. Revenue rose 11.4% to $106.158 billion from $95.294 billion, and the company issued full-year EPS guidance of $38.80 to $39.20, underscoring stronger-than-prior-year performance and a constructive outlook for the business.

Analysis

Market structure: McKesson’s beat (Q3 revenue +11.4%, adj EPS $9.34) reinforces distributor-led scale advantages — direct winners are large wholesalers (MCK, ABC, CAH) and integrated specialty pharmacies that capture volume and margin; losers are independent regional distributors and small specialty distributors that lose negotiating leverage. Faster revenue growth than peers would suggest either share gains or higher mix of specialty/biologics; if MCK sustains >10% top-line growth for two consecutive quarters it can press for tighter payer/provider contracts and incremental gross-margin expansion of ~50–150 bps over 12–18 months.

Risks: Tail scenarios include a material regulatory shock (PBM reform or drug-pricing caps) shaving 100–300 bps off gross spreads, or a major opioid/controlled-substance litigation judgment creating >$1–3B one-time liabilities; operational supply-chain disruptions (manufacturing recalls) could dent revenue by several percent for a quarter. Immediate (days) risk is a sentiment gap after the print; short-term (3–6 months) risk centers on guidance credibility and working-capital swings; long-term (≥12 months) depends on reimbursement policy and M&A integration outcomes.

Trade implications: Favor a tactical overweight MCK vs peers: long MCK for 3–9 months to capture re-rating if guidance holds, paired with short ABC or CAH to hedge sector/regulatory exposure. Options play: sell near-term implied volatility (30–60d) via covered calls or cash-secured puts if IV compresses post-beat, and buy 6–12 month 10% OTM calls as leveraged upside. Cross-asset: prefer IG credit exposure to high-quality healthcare corporates and avoid long-duration sovereign exposure if volatility rises.

Contrarian angles: Consensus assumes durable margin improvement — check cash conversion and one-offs (GAAP vs adj difference here was ~$31M); if free cash flow fails to translate to buybacks/dividend growth the multiple may contract. Historical parallels: post-beat distributor reratings reversed when regulatory focus intensified (2017–2019 cycle). If near-term political headlines on PBMs intensify, upside may be limited and short-term volatility will create entry points.

Key Decisions for Investors

• Establish a 2–3% long position in MCK (ticker MCK) within the equity sleeve over the next 5 trading days; target total return 10–15% over 3–9 months and set a hard stop-loss at -8% from entry to protect against policy shocks.
• Implement a pair trade: long MCK 2.5% / short AmerisourceBergen (ABC) 1.5% for a 3–6 month horizon to capture relative share/operational leverage; unwind if spread vs ABC tightens by <100 bps or if ABC announces superior guidance.
• Options strategy: sell 30–60 day covered calls on 50% of the MCK long position to harvest compressed IV post-earnings while buying 6–12 month MCK calls 10% OTM sized at 0.5–1% notional for asymmetric upside exposure.
• Monitor regulatory catalysts: if Congress/administration advance PBM/drug-pricing reform with an estimated >100 bps impact on gross spreads within 90 days, reduce MCK to underweight within 10 trading days and shift proceeds to investment-grade healthcare credit (BBB/BBB+) for defensive yield.